Semaglutide Improves Cognitive Function in People with Depression and Obesity
A randomized clinical trial found semaglutide improved cognitive dysfunction in overweight/obese adults with major depressive disorder over 16 weeks.
Quick Facts
What This Study Found
Semaglutide significantly improved cognitive dysfunction in overweight/obese adults with major depressive disorder in a 16-week randomized clinical trial.
Key Numbers
How They Did This
16-week randomized, double-blind, placebo-controlled, parallel-group trial (NCT04466345); overweight/obese adults with DSM-5 MDD and cognitive impairment.
Why This Research Matters
This is landmark evidence — the first RCT showing a GLP-1 RA improves cognition in depression. Cognitive dysfunction is one of the most disabling aspects of depression and lacks targeted treatments.
The Bigger Picture
If GLP-1 RAs can treat cognitive dysfunction in depression, they could become a novel class of cognitive enhancers for psychiatric conditions — a completely new therapeutic application.
What This Study Doesn't Tell Us
Participants were overweight/obese — unclear if cognitive benefits extend to normal-weight depression patients; relatively short 16-week duration; adjunctive therapy (added to existing treatment).
Questions This Raises
- ?Is the cognitive benefit driven by metabolic improvement, direct brain effects, or both?
- ?Will longer treatment maintain or enhance cognitive improvements?
Trust & Context
- Key Stat:
- First RCT evidence Semaglutide improved cognitive dysfunction in depressed, overweight/obese adults over 16 weeks
- Evidence Grade:
- Randomized, double-blind, placebo-controlled trial — the gold standard for clinical evidence. Published in Med (Cell Press).
- Study Age:
- Published 2026 in Med. Trial registration: NCT04466345.
- Original Title:
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
- Published In:
- Med (New York, N.Y.), 7(1), 100916 (2026)
- Authors:
- Badulescu, Sebastian(2), Gill, Hartej(2), Shah, Hiya, Brudner, Ryan, Phan, Lee, Di Vincenzo, Joshua D, Tabassum, Aniqa, Armanyous, Michael, Llach, Cristian-Daniel, Rosenblat, Joshua D, McIntyre, Roger S, Mansur, Rodrigo B
- Database ID:
- RPEP-14811
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide help with depression-related brain fog?
This clinical trial showed semaglutide improved cognitive function in people with depression and obesity — the first evidence from a randomized trial that GLP-1 drugs may help with depression-related cognitive problems.
Does this mean semaglutide is an antidepressant?
The study focused on cognitive dysfunction, not depression symptoms overall. While the cognitive improvement is significant, semaglutide was used as an add-on to existing depression treatment, not as a standalone antidepressant.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14811APA
Badulescu, Sebastian; Gill, Hartej; Shah, Hiya; Brudner, Ryan; Phan, Lee; Di Vincenzo, Joshua D; Tabassum, Aniqa; Armanyous, Michael; Llach, Cristian-Daniel; Rosenblat, Joshua D; McIntyre, Roger S; Mansur, Rodrigo B. (2026). Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.. Med (New York, N.Y.), 7(1), 100916. https://doi.org/10.1016/j.medj.2025.100916
MLA
Badulescu, Sebastian, et al. "Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.." Med (New York, 2026. https://doi.org/10.1016/j.medj.2025.100916
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide for the treatment of cognitive dysfunction in ma..." RPEP-14811. Retrieved from https://rethinkpeptides.com/research/badulescu-2026-semaglutide-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.